Search results
Results from the WOW.Com Content Network
Ionis Pharmaceuticals Stock Price And Volume Action Ionis Pharmaceuticals (NASDAQ:IONS) is currently down 17.47% to a price of $46.29. Tuesday the stock has been traded at a volume of 2.55 million ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics.The company has three commercially approved medicines: Spinraza (), Tegsedi (), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease (together with Roche), tofersen for SOD1-ALS, AKCEA ...
Biogen stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100 and the company is listed on the NASDAQ stock exchange under the ticker symbol, BIIB. [11] In May 2006, the company announced it would acquire cancer specialist, Conforma Therapeutics for $250 million. [12]
For premium support please call: 800-290-4726 more ways to reach us
On the New York Stock Exchange (NYSE), one type of trading curb is referred to as a "circuit breaker". These limits were put in place beginning in January 1988 (weeks after Black Monday occurred in 1987) in order to reduce market volatility and massive panic sell-offs, giving traders time to reconsider their transactions.
(Reuters) -The U.S. Food and Drug Administration has approved Ionis Pharmaceuticals' drug to treat a rare genetic disorder, making it the company's first wholly-owned drug, the health regulator's ...